190 related articles for article (PubMed ID: 31499493)
21. Efficacy of selective venous catheterization in localizing a small androgen-producing tumor in ovary.
Nishiyama S; Hirota Y; Udagawa Y; Kato R; Hayakawa N; Tukada K
Med Sci Monit; 2008 Feb; 14(2):CS9-12. PubMed ID: 18227769
[TBL] [Abstract][Full Text] [Related]
22. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors.
McCluggage WG; McKenna M; McBride HA
Int J Gynecol Pathol; 2007 Jul; 26(3):322-7. PubMed ID: 17581419
[TBL] [Abstract][Full Text] [Related]
23. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
Schultz KAP; Harris AK; Finch M; Dehner LP; Brown JB; Gershenson DM; Young RH; Field A; Yu W; Turner J; Cost NG; Schneider DT; Stewart DR; Frazier AL; Messinger Y; Hill DA
Gynecol Oncol; 2017 Dec; 147(3):521-527. PubMed ID: 29037807
[TBL] [Abstract][Full Text] [Related]
24. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
Kaltsas GA; Isidori AM; Kola BP; Skelly RH; Chew SL; Jenkins PJ; Monson JP; Grossman AB; Besser GM
J Clin Endocrinol Metab; 2003 Jun; 88(6):2634-43. PubMed ID: 12788867
[TBL] [Abstract][Full Text] [Related]
25. Sertoli-Leydig cell tumor - a rare androgen secreting ovarian tumor in postmenopausal women. Case report and review of literature.
Gheorghisan-Galateanu A; Fica S; Terzea DC; Caragheorgheopol A; Horhoianu V
J Cell Mol Med; 2003; 7(4):461-71. PubMed ID: 14754515
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone suppression test versus selective ovarian and adrenal vein catheterization in identifying virilizing tumors in postmenopausal hyperandrogenism - a systematic review and meta-analysis.
Tng EL; Tan JM
Gynecol Endocrinol; 2021 Jul; 37(7):600-608. PubMed ID: 33660585
[TBL] [Abstract][Full Text] [Related]
27. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women.
Bahaeldein E; Brassill MJ
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30481153
[TBL] [Abstract][Full Text] [Related]
28. [Androgenic alopecia revealing an androgen secreting ovarian tumor].
Roux-Guinot S; Gorin I; Vadrot D; Djid R; Bethoux JP; Escande JP
Ann Dermatol Venereol; 2001 Nov; 128(11):1241-4. PubMed ID: 11908171
[TBL] [Abstract][Full Text] [Related]
29. [Sex cord-stromal tumors of the ovary : Current aspects with a focus on granulosa cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas].
Kommoss F; Lehr HA
Pathologe; 2019 Feb; 40(1):61-72. PubMed ID: 30659330
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor.
Bohlmann MK; Rabe T; Sinn HP; Strowitzki T; Von Wolff M
Gynecol Endocrinol; 2005 Sep; 21(3):138-41. PubMed ID: 16335905
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of endocrinally active ovarian tumors.
Moltz L
Int J Gynecol Pathol; 1993 Apr; 12(2):170-2. PubMed ID: 8463041
[TBL] [Abstract][Full Text] [Related]
32. An immunohistochemical and molecular analysis of problematic and unclassified ovarian sex cord-stromal tumors.
Stewart CJ; Alexiadis M; Crook ML; Fuller PJ
Hum Pathol; 2013 Dec; 44(12):2774-81. PubMed ID: 24134930
[TBL] [Abstract][Full Text] [Related]
33. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study.
Kommoss F; Oliva E; Bhan AK; Young RH; Scully RE
Mod Pathol; 1998 Jul; 11(7):656-64. PubMed ID: 9688187
[TBL] [Abstract][Full Text] [Related]
34. The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.
Wang Y; Chen J; Yang W; Mo F; Senz J; Yap D; Anglesio MS; Gilks B; Morin GB; Huntsman DG
Neoplasia; 2015 Aug; 17(8):650-60. PubMed ID: 26408257
[TBL] [Abstract][Full Text] [Related]
35. DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects.
Kato N; Kusumi T; Kamataki A; Tsunoda R; Fukase M; Kurose A
Hum Pathol; 2017 Jan; 59():41-47. PubMed ID: 27664536
[TBL] [Abstract][Full Text] [Related]
36. 14-3-3 sigma is a useful immunohistochemical marker for diagnosing ovarian granulosa cell tumors and steroid cell tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2013 Mar; 32(2):156-62. PubMed ID: 23370648
[TBL] [Abstract][Full Text] [Related]
37. Virilization due to androgen hypersecretion in a patient with ovarian leydig cell tumor: diagnostic and psychosocial implications.
Juniarto AZ; Setiawati BA; Ediati A; van der Zwan YG; Looijenga LH; de Jong FH; Dessens A; Drop SL; Faradz SM
Acta Med Indones; 2013 Apr; 45(2):130-5. PubMed ID: 23770793
[TBL] [Abstract][Full Text] [Related]
38. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors.
Zhao C; Vinh TN; McManus K; Dabbs D; Barner R; Vang R
Am J Surg Pathol; 2009 Mar; 33(3):354-66. PubMed ID: 19033865
[TBL] [Abstract][Full Text] [Related]
39. Hyperandrogenism caused by ovarian Leydig cell tumour: finding the needle in a haystack.
Tong CV; Tai YT
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33318251
[TBL] [Abstract][Full Text] [Related]
40. Postmenopausal androgen secreting ovarian tumour: pathophysiological implications; a case report.
Pérez A; Calaf J; Webb SM; Prat J; de Leiva A
Eur J Obstet Gynecol Reprod Biol; 1990 Apr; 35(1):97-105. PubMed ID: 2107106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
